NasdaqGS:MRNABiotechs
Does Moderna’s Wider 2026 Loss Amid Pipeline Spend Change The Bull Case For MRNA?
In the past quarter, Moderna, Inc. reported second-quarter 2026 revenue of US$145 million versus US$142 million a year earlier, with a net loss of US$782 million and basic loss per share from continuing operations of US$1.97, while also updating investors on its norovirus and influenza vaccine programs.
Across the first half of 2026, revenue rose to US$534 million from US$250 million, but the net loss widened to US$2.13 billion and basic loss per share from continuing operations increased to...